BIOCRYST PHARMACEUTICALS INC Contracts & Agreements

BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (as amended and restated as of April 22, 2024) (Filed With SEC on June 13, 2024)

Cash and cash equivalents (Filed With SEC on November 8, 2023)

BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (as amended and restated as of April 24, 2023) (Filed With SEC on June 14, 2023)

Drug/Drug Candidate (Filed With SEC on February 27, 2023)

Cash and cash equivalents (Filed With SEC on November 4, 2022)

Amendment, dated August 10, 2022, to the Contract dated September 1, 2018 between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services (Filed With SEC on August 25, 2022)

Cash and cash equivalents (Filed With SEC on August 5, 2022)

BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (as amended and restated as of April 18, 2022) (Filed With SEC on June 7, 2022)

the preclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO(berotralstat), BCX9930,... (Filed With SEC on May 9, 2022)

EX-10.14 EX-10.72 EX-10.76 EX-10.101 EX-10.102 EX-10.103 EX-10.104 EX-21 EX-23 EX-31.1 EX-31.2 EX-32.1 EX-32.2 EX-101 EX-104 (Filed With SEC on February 28, 2022)

EX-10.72 EX-10.76 EX-10.101 EX-10.102 EX-10.103 EX-10.104 EX-21 EX-23 EX-31.1 EX-31.2 EX-32.1 EX-32.2 EX-101 EX-104 (Filed With SEC on February 28, 2022)

EX-10.76 EX-10.101 EX-10.102 EX-10.103 EX-10.104 EX-21 EX-23 EX-31.1 EX-31.2 EX-32.1 EX-32.2 EX-101 EX-104 (Filed With SEC on February 28, 2022)

FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (Filed With SEC on November 4, 2021)

Amendment, dated August 27, 2021, to the Contract dated September 1, 2018 between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services (Filed With SEC on September 1, 2021)

Separation Agreement and Release, dated August 8, 2021, by and between BioCryst Pharmaceuticals, Inc. and Megan Sniecinski (Filed With SEC on August 9, 2021)

BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (as amended and restated as of April 1, 2021) (Filed With SEC on May 26, 2021)

BioCryst Pharmaceuticals, Inc. Employee Stock Purchase Plan (as amended and restated as of April 1, 2021) (Filed With SEC on May 26, 2021)

BIOCRYST PHARMACEUTICALS, INC. STOCK INCENTIVE PLAN NOTICE OF RESTRICTED STOCK UNIT AWARD (Filed With SEC on May 7, 2021)

thepreclinical development, clinical development, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO (berotralstat), BCX9930,... (Filed With SEC on March 1, 2021)

BioCryst Pharmaceuticals, Inc. Annual Incentive Plan, effective as of December 16, 2020 (Filed With SEC on December 17, 2020)

THIRD aMENDMENT TO SECOND AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (Filed With SEC on November 6, 2020)

Amendment, dated August 31, 2020, to the Contract dated September 1, 2018 between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services (Filed With SEC on September 3, 2020)

Underwriting Agreement, dated May 27, 2020, by and among BioCryst Pharmaceuticals, Inc. and J.P. Morgan Securities LLC and Piper Sandler & Co., as representatives of the... (Filed With SEC on June 1, 2020)

Form of Warrant to Purchase Common Stock, dated June 1, 2020 (Filed With SEC on June 1, 2020)

BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (as amended and restated as of March 19, 2020) (Filed With SEC on May 13, 2020)

BioCryst Pharmaceuticals, Inc. Employee Stock Purchase Plan (as amended and restated as of March 19, 2020) (Filed With SEC on May 13, 2020)

Cash and cash equivalents (Filed With SEC on May 11, 2020)

Description of Common Stock (Filed With SEC on March 13, 2020)

Drug/Drug Candidate (Filed With SEC on March 13, 2020)

Form of Warrant to Purchase Common Stock, dated November 21, 2019 (Filed With SEC on November 21, 2019)

Securities Purchase Agreement, dated November 19, 2019, among BioCryst Pharmaceuticals, Inc., Baker Brothers Life Sciences, L.P. and 667, L.P (Filed With SEC on November 20, 2019)

Underwriting Agreement, dated November 13, 2019, by and between BioCryst Pharmaceuticals, Inc. and J.P. Morgan Securities LLC, as representative of the underwriters named in... (Filed With SEC on November 18, 2019)

Cash and cash equivalents (Filed With SEC on November 8, 2019)

Amendment dated as of September 23, 2019 to the Contract dated September 1, 2018 between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services (Filed With SEC on September 26, 2019)

Cash and cash equivalents (Filed With SEC on August 8, 2019)

BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (as Amended and Restated April 12, 2019) (Filed With SEC on June 4, 2019)

Cash and cash equivalents (Filed With SEC on May 9, 2019)

Financial Statements (Filed With SEC on November 8, 2018)

BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (as Amended and Restated September 17, 2018) (Filed With SEC on October 31, 2018)

Contract dated as of September 1, 2018 between BioCryst Pharmaceuticals, Inc. and the Centers for Disease Control and Prevention (Filed With SEC on September 6, 2018)

Underwriting Agreement, dated August 1, 2018, by and among BioCryst Pharmaceuticals, Inc. and J.P. Morgan Securities LLC and Jefferies LLC, as representatives of the underwriters... (Filed With SEC on August 6, 2018)

Cash and cash equivalents (Filed With SEC on May 9, 2018)

Amendment #9 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human... (Filed With SEC on March 12, 2018)

Cash and cash equivalents (Filed With SEC on November 8, 2017)

Underwriting Agreement, dated September 12, 2017, by and among BioCryst Pharmaceuticals, Inc., J. P. Morgan Securities LLC and Barclays Capital Inc., as representatives of the... (Filed With SEC on September 15, 2017)

BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (as Amended and Restated April 3, 2017) (Filed With SEC on May 30, 2017)

Registration Rights Agreement, dated March 15, 2017, by and between BioCryst Pharmaceuticals, Inc., 667, L.P., and Baker Brothers Life Sciences, L.P (Filed With SEC on March 17, 2017)

BIOCRYST PHARMACEUTICALS, INC. 5,294,118 Shares of Common Stock (par value $0.01 per share) Underwriting Agreement (Filed With SEC on March 15, 2017)

13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS, IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14. (Filed With SEC on November 8, 2016)

CREDIT AND SECURITY AGREEMENT (Filed With SEC on November 8, 2016)

Statement of Work BioCryst Pharmaceuticals Contract HHSO100201500007C BCX4430 NDA Enabling CMC and Non-Clinical Toxicology Studies (Filed With SEC on August 8, 2016)

Pursuant to 17 CFR 20.24b-2, confidential information has been omittedin places marked "***" and has been filed separately with the Securities and Exchange Commission pursuant to... (Filed With SEC on November 6, 2015)

Pursuant to 17 CFR 20.24b-2, confidential information has been omitted in places marked *** and has been filed separately with the Securities and Exchange Commission pursuant to a... (Filed With SEC on August 7, 2015)

1. DEFINITIONS AND INTERPRETATION (Filed With SEC on August 7, 2015)

Pursuant to 17 CFR 20.24b-2, confidential information has been omittedin places marked "***" and has been filed separately with the Securities and Exchange Commission pursuant to... (Filed With SEC on August 7, 2015)

BIOCRYST PHARMACEUTICALS, INC. STANDARD STOCK OPTION AGREEMENT WITNESSETH: (Filed With SEC on March 2, 2015)

BIOCRYST PHARMACEUTICALS, INC. STOCK INCENTIVE PLAN NOTICE OF RESTRICTED STOCK UNIT AWARD (Filed With SEC on March 2, 2015)

Cash and cash equivalents (Filed With SEC on November 7, 2014)

BIOCRYST PHARMACEUTICALS, INC. 10,000,000 Shares of Common Stock (par value $0.01 per share) Underwriting Agreement (Filed With SEC on June 3, 2014)

BIOCRYST PHARMACEUTICALS, INC. STOCK INCENTIVE PLAN (AS AMENDED AND RESTATED March 8, 2014) ARTICLE ONE GENERAL PROVISIONS (Filed With SEC on May 5, 2014)

BIOCRYST PHARMACEUTICALS, INC. EMPLOYEE STOCK PURCHASE PLAN (Amended and Restated March 8, 2014) (Filed With SEC on May 5, 2014)

Exhibit A (ProprietaryInformation and Inventions Agreement) EMPLOYEES PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT (Filed With SEC on March 10, 2014)

Supplies/Services (Filed With SEC on March 10, 2014)

Option/Increment Description (Filed With SEC on March 10, 2014)

Contract No. HHSN272201300017C Modification No. 2 (Filed With SEC on March 10, 2014)

CONTRACT TABLE OF CONTENTS (Filed With SEC on November 8, 2013)

BIOCRYST PHARMACEUTICALS, INC. 4,000,000 Shares of Common Stock UNDERWRITING AGREEMENT (Filed With SEC on August 5, 2013)

FOURTH AMENDMENT TO LEASE AGREEMENT (Filed With SEC on March 11, 2013)

MUTUAL TERMINATION AND RELEASE AGREEMENT (Filed With SEC on November 30, 2012)

EXECUTION COPY MERGER AGREEMENT BY AND AMONG PRESIDIO PHARMACEUTICALS, INC., S SUB, INC., BIOCRYST PHARMACEUTICALS, INC. AND SHAREHOLDER REPRESENTATIVE SERVICES LLC, SOLELY IN ITS... (Filed With SEC on October 22, 2012)

INVESTOR FINANCING AGREEMENT by and among BIOCRYST PHARMACEUTICALS, INC. and THE INVESTORS LISTED ON SCHEDULE 1 Dated as of October 17, 2012 TABLE OF CONTENTS (Filed With SEC on October 22, 2012)

VOTING AND POST-CLOSING LOCK-UP AGREEMENT (Filed With SEC on October 22, 2012)

SIDE AGREEMENT TO INVESTOR FINANCING AGREEMENT (Filed With SEC on October 22, 2012)

Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked * * * and has been filed separately with the Securities and Exchange Commission pursuant... (Filed With SEC on August 8, 2012)

BIOCRYST PHARMACEUTICALS, INC. STOCK INCENTIVE PLAN (AS AMENDED AND RESTATED MARCH 29, 2012) ARTICLE ONE GENERAL PROVISIONS (Filed With SEC on May 25, 2012)

BIOCRYST PHARMACEUTICALS, INC. EMPLOYEE STOCK PURCHASE PLAN (Amended and Restated March 29, 2012) (Filed With SEC on May 25, 2012)

BioCryst Pharmaceuticals, Inc. Annual Incentive Plan Communication Summary for Participants Effective March 9, 2012 BioCryst Pharmaceuticals, Inc. Annual Incentive Plan Effective... (Filed With SEC on March 12, 2012)

AMENDED AND RESTATED DEVELOPMENT AND LICENSE AGREEMENT BY AND BETWEEN BIOCRYST PHARMACEUTICALS, INC. AND MUNDIPHARMA INTERNATIONAL CORPORATION LIMITED (Filed With SEC on March 6, 2012)

FIFTH AMENDMENT AGREEMENT (Filed With SEC on March 6, 2012)

EX-101 INSTANCE DOCUMENT (Filed With SEC on August 4, 2011)

BioCryst Pharmaceuticals, Inc. 4505 Emperor Blvd, Suite 200 Durham, NC 27703 ###-###-#### phone ###-###-#### fax www.biocryst.com (Filed With SEC on May 25, 2011)

BIOCRYST PHARMACEUTICALS, INC. STOCK INCENTIVE PLAN (AS AMENDED AND RESTATED FEBRUARY 17, 2011) (Filed With SEC on May 17, 2011)

Cash and cash equivalents (Filed With SEC on May 6, 2011)

Peramivir, a neuraminidase inhibitor for the potential treatment of influenza (Filed With SEC on March 15, 2011)

Financial Statements (Filed With SEC on August 6, 2010)

John L. Higgins (Filed With SEC on May 18, 2010)

Signature Date (Filed With SEC on March 9, 2010)

THIRD AMENDMENT AGREEMENT (Filed With SEC on March 9, 2010)

5,000,000 Shares BIOCRYST PHARMACEUTICALS, INC. COMMON STOCK, PAR VALUE $0.01 PER SHARE UNDERWRITING AGREEMENT (Filed With SEC on November 24, 2009)

Financial Statements (Filed With SEC on November 6, 2009)

Name TitleWilliam P. Sheridan, M.D. Chief Medical Officer, Principal InvestigatorElliott Berger, Ph.D. Sr. Vice President, Regulatory AffairsWalter G. Gowan, Ph.D. Vice President... (Filed With SEC on March 6, 2009)

FIRST AMENDMENT TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (Filed With SEC on March 6, 2009)

SEVERANCE AGREEMENT AND GENERAL RELEASE (Filed With SEC on March 6, 2009)

AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 1. CONTRACT ID CODE PAGE OF PAGES 1 1 2. AMENDMENT/MODIFICATION NO: 3. EFFECTIVE DATE 4. REQUISITION/PURC 5. PROJECT NO. (If... (Filed With SEC on November 10, 2008)

Cash and cash equivalents (Filed With SEC on August 8, 2008)

EX-10.1 ANNUAL INCENTIVE PLAN (Filed With SEC on March 4, 2008)

EX-10.2 EXECUTIVE RELOCATION POLICY (Filed With SEC on March 4, 2008)

EX-10.3 AMENDMENT TO EMPLOYMENT LETTER AGREEMENT (Filed With SEC on March 4, 2008)

EX-10.4 FORM OF NOTICE OF GRANT NON-EMPLOYEE DIRECTOR (Filed With SEC on March 4, 2008)

EX-10.5 FORM OF NOTICE OF GRANT OF STOCK OPTION (Filed With SEC on March 4, 2008)

EX-10.6 AMENDMENT #3 TO THE AGREEMENT (Filed With SEC on March 4, 2008)

AMENDMENT OF BIOCRYST (Filed With SEC on August 9, 2007)

BIOCRYST PHARMACEUTICALS, INC. STOCK INCENTIVE PLAN (formerly the BioCryst Pharmaceuticals, Inc. 1991 Stock Option Plan) (Filed With SEC on August 9, 2007)

Page 2 of 27 (Filed With SEC on August 9, 2007)

STATE OF ALABAMA ) SHELBY COUNTY ) THIRD AMENDMENT TO LEASE AGREEMENT (Filed With SEC on August 9, 2007)

STOCK AND WARRANT PURCHASE AGREEMENT (Filed With SEC on August 7, 2007)

FORM OF WARRANT (Filed With SEC on August 7, 2007)

Cash and cash equivalents (Filed With SEC on May 10, 2007)

EX-10.12 AMENDED AND RESTATED EMPLOYMENT LETTER AGREEMENT (Filed With SEC on March 14, 2007)

BIOCRYST PHARMACEUTICALS, INC. STOCK INCENTIVE PLAN (formerly the BioCryst Pharmaceuticals, Inc. 1991 Stock Option Plan) (AMENDED AND RESTATED EFFECTIVE MARCH 7, 2006) ARTICLE ONE... (Filed With SEC on August 9, 2006)

License Agreement (Filed With SEC on May 2, 2006)

Development and License Agreement (Filed With SEC on December 22, 2005)

Stock Purchase Agreement (Filed With SEC on December 16, 2005)

Nomination and Observer Agreement (Filed With SEC on December 16, 2005)

LICENSE AGREEMENT BETWEEN ALBERT EINSTEIN COLLEGE OF MEDICINE, INDUSTRIAL RESEARCH, LTD AND BIOCRYST PHARMACEUTICALS, INC. Statement 1 1. Definitions 2 1.01 Field 2 1.02 Agreement... (Filed With SEC on November 30, 2005)

Stock Purchase Agreement (Filed With SEC on February 17, 2005)

Placement Agency Agreement (Filed With SEC on February 17, 2005)

Category

Industry

Companies

Contracts

BIOCRYST PHARMACEUTICALS INC Contracts & Agreements